Blood Cancer J 2018 May 24
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
Related Questions
Would you consider Dara-CyBorD or a MM triplet/quadruplet such as VRd or Dara-VRd?
New comment by Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center ( August 19, 2022)
Agreed - this has been a fascinating discussion on all fronts! In our case, the added wrinkle was that the patient was a Kaiser patient where the local doctor thought a Dara-C...